Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: Cell Rep. 2016 Nov 22;17(9):2367–2381. doi: 10.1016/j.celrep.2016.10.077

Figure 5. BRCA1-mutated SUM149PT and HCC1937 cells are sensitized to PARP inhibition by siRNA- or dinaciclib-mediated depletion of the BRCA1-PALB2-BRCA2 axis and RAD51.

Figure 5

(A) SUM149PT cells were transfected with the indicated siRNAs targeting BRCA1, BRCA2 or PALB2, followed by veliparib treatment at the indicated concentrations. Colony formation was assessed over a 14-day period. (B) Similar experiments were performed with HCC1937 cells using siRNAs targeting BRCA2 and PALB2. (C) Cells were treated with vehicle (0 nM) or the indicated concentrations of dinaciclib for 24 hrs and nuclear lysates subjected to Western blotting with the indicated antibodies. (D) Cells were pretreated with vehicle or 10 nM dinaciclib for 18 hours followed by 10 Gy IR. RAD51 and γH2AX focus formation was assessed by immunofluorescence 6 hrs after IR. (E) Quantification of RAD51 focus formation 6 hrs after IR in cells pretreated with vehicle (0 nM) or the indicated concentrations of dinaciclib (* P < 0.0001 for dinaciclib vs. vehicle). (F) Cells were treated with the indicated concentrations of veliparib in the absence or presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.